Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women

Abstract

Preeclampsia is a systemic syndrome that seems to originate from the placenta and is associated with an imbalance between angiogenic factors in the maternal circulation. One of the well-studied and widely used factors is PlGF (placental growth factor), the levels of which drop in women destined to develop preeclampsia. This drop is known to precede the development of actual signs and symptoms of preeclampsia, thus proving to be a useful screening tool in predicting the disease. The literature varies widely in terms of the clinical usefulness of the test. We conducted a meta-analysis to study the predictive accuracy of PlGF in asymptomatic women. Our analysis included 40 studies with 3189 cases of preeclampsia and 89 498 controls. The overall predictive odds ratio of the test was 9 (6–13). Subgroup analysis evaluating various PlGF thresholds demonstrated that the predictive values were highest for PlGF levels between 80 and 120 pg/mL with a high predictive odds ratio of 25 (7–88), a sensitivity of 0.78 (95% CI, 0.67–0.86), a specificity of 0.88 (95% CI, 0.75–0.95), a positive likelihood ratio of 6.3 (95% CI, 2.7–14.7), and a negative likelihood ratio of 0.26 (95% CI, 0.16–0.42). Additionally, the accuracy was higher when the test was performed after 14 weeks of gestation (OR, 10 [7–15]) and for prediction of early onset preeclampsia (OR, 18 [9–37]). We conclude that PlGF is a useful screening tool to predict preeclampsia. Nonetheless, its utility should be judged with caution and randomized controlled trials are warranted to explore if its implementation improves perinatal outcomes in asymptomatic women.